In recent trading session, ATAI Life Sciences N.V (NASDAQ:ATAI) saw 0.49 million shares changing hands at last check today with its beta currently measuring 1.24. Company’s recent per share price level of $2.07 trading at $0.03 or 1.23% at last check today assigns it a market valuation of $400.60M. That most recent trading price of ATAI’s stock is at a discount of -37.68% from its 52-week high price of $2.85 and is indicating a premium of 50.24% from its 52-week low price of $1.03.
For ATAI Life Sciences N.V (ATAI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Upright in the green today for gaining 1.23%, in the last five days ATAI remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $2.07 price level, adding 16.53% to its value on the day. ATAI Life Sciences N.V’s shares saw a change of 55.26% in year-to-date performance and have moved -9.03% in past 5-day. ATAI Life Sciences N.V (NASDAQ:ATAI) showed a performance of 35.86% in past 30-days.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 65.5% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -189.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -189.86% for stock’s current value.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
This year revenue growth is estimated to rise 159.03% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 250k for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 44.19% during past 5 years.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
WALLEYE CAPITAL LLC is the top institutional holder at ATAI for having 2.76 million shares of worth $3.67 million. And as of 2024-06-30, it was holding 1.7226 of the company’s outstanding shares.
The second largest institutional holder is MORGAN STANLEY, which was holding about 2.72 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.7111 of outstanding shares, having a total worth of $3.62 million.
On the other hand, iShares Biotechnology ETF and Morgan Stanley Inst Fund Inc-Inception Port are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024, the former fund manager was holding 771.79 shares of worth $1.59 million or 0.46% of the total outstanding shares. The later fund manager was in possession of 511.99 shares on Sep 30, 2024, making its stake of worth around $1.05 million in the company or a holder of 0.31% of company’s stock.
